AUPH Aurinia Pharmaceuticals Inc

4.71
-0.08  -2%
Previous Close 4.79
Open 4.79
Price To Book 3.44
Market Cap 432,345,030
Shares 94,285,008
Volume 1,262,110
Short Ratio
Av. Daily Volume 991,334
Stock charts supplied by TradingView

NewsSee all news

  1. Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global

  2. Aurinia Establishes At-the-Market Facility

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has

  3. Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21st Annual H.C.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 trial to be initiated 4Q 2019.
Voclosporin Ophthalmic Solution (VOS)
Dry eye syndrome
Phase 2 interim data due 2020.
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 3 data due 4Q 2019.
Voclosporin - AURORA
Lupus
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2
Lupus

Latest News

  1. Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global

  2. Aurinia Establishes At-the-Market Facility

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has

  3. Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21st Annual H.C.